Location History:
- Vienna, AT (2010)
- St Louis, FR (2013)
- St. Louis, FR (2014 - 2015)
Company Filing History:
Years Active: 2010-2015
Title: Christoph Schwaerzler: Innovator in Autoimmune and Inflammatory Disorder Treatments
Introduction
Christoph Schwaerzler is a notable inventor based in St. Louis, France. He has made significant contributions to the field of biotechnology, particularly in the development of treatments for autoimmune and inflammatory disorders. With a total of 5 patents to his name, Schwaerzler's work is recognized for its potential impact on patient care.
Latest Patents
Among his latest patents, Schwaerzler has developed anti-IL12Rβ1 antibodies and their use in treating autoimmune and inflammatory disorders. This invention relates to antibodies that specifically bind to IL12Rβ1, which is the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention focuses on specific antibodies that act as IL12 and IL23 receptor antagonists. These antibodies are capable of inhibiting IL12/IL18 induced IFNγ production of blood cells. The compositions and methods of use for these antibodies aim to treat pathological disorders that can be managed by inhibiting IFNγ production and IL12/IL23 signaling, including rheumatoid arthritis, psoriasis, and inflammatory bowel diseases.
Career Highlights
Schwaerzler is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to further his research and development efforts in the field of immunology. His innovative approaches have positioned him as a key figure in the advancement of therapeutic options for patients suffering from complex autoimmune conditions.
Collaborations
Throughout his career, Schwaerzler has collaborated with esteemed colleagues, including Christoph Heusser and Jose M Carballido Herrera. These collaborations have fostered a productive environment for innovation and have contributed to the success of his research initiatives.
Conclusion
Christoph Schwaerzler's contributions to the field of biotechnology, particularly in the development of treatments for autoimmune and inflammatory disorders, highlight his role as a significant inventor. His patents and ongoing work at Novartis AG continue to pave the way for advancements in patient care and treatment options.